285 related articles for article (PubMed ID: 28791783)
21. Hemorrhage owing to cerebral cavernous malformation: imaging, clinical, and histopathological considerations.
Kurihara N; Suzuki H; Kato Y; Rikimaru H; Sato A; Uenohara H
Jpn J Radiol; 2020 Jul; 38(7):613-621. PubMed ID: 32221793
[TBL] [Abstract][Full Text] [Related]
22. Quantitative susceptibility map analysis in preterm neonates with germinal matrix-intraventricular hemorrhage.
Tortora D; Severino M; Sedlacik J; Toselli B; Malova M; Parodi A; Morana G; Fato MM; Ramenghi LA; Rossi A
J Magn Reson Imaging; 2018 Nov; 48(5):1199-1207. PubMed ID: 29746715
[TBL] [Abstract][Full Text] [Related]
23. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.
Mikati AG; Tan H; Shenkar R; Li L; Zhang L; Guo X; Larsson HB; Shi C; Liu T; Wang Y; Shah A; Edelman RR; Christoforidis G; Awad I
Stroke; 2014 Feb; 45(2):598-601. PubMed ID: 24302484
[TBL] [Abstract][Full Text] [Related]
24. Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations.
Zou X; Hart BL; Mabray M; Bartlett MR; Bian W; Nelson J; Morrison LA; McCulloch CE; Hess CP; Lupo JM; Kim H
Neuroradiology; 2017 Jul; 59(7):685-690. PubMed ID: 28534135
[TBL] [Abstract][Full Text] [Related]
25. A rupture risk analysis of cerebral cavernous malformation associated with developmental venous anomaly using susceptibility-weighted imaging.
Zhang S; Ma L; Wu C; Wu J; Cao Y; Wang S; Zhao J
Neuroradiology; 2020 Jan; 62(1):39-47. PubMed ID: 31482190
[TBL] [Abstract][Full Text] [Related]
26. Comparison of quantitative susceptibility mapping methods on evaluating radiation-induced cerebral microbleeds and basal ganglia at 3T and 7T.
Chen Y; Genc O; Poynton CB; Banerjee S; Hess CP; Lupo JM
NMR Biomed; 2022 May; 35(5):e4666. PubMed ID: 35075701
[TBL] [Abstract][Full Text] [Related]
27. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.
Girard R; Zeineddine HA; Fam MD; Mayampurath A; Cao Y; Shi C; Shenkar R; Polster SP; Jesselson M; Duggan R; Mikati AG; Christoforidis G; Andrade J; Whitehead KJ; Li DY; Awad IA
Transl Stroke Res; 2018 Feb; 9(1):34-43. PubMed ID: 28819935
[TBL] [Abstract][Full Text] [Related]
28. Multiple cerebral cavernous malformations: Clinical course of confirmed, assumed and non-familial disease.
Santos AN; Rauschenbach L; Saban D; Chen B; Darkwah Oppong M; Herten A; Gull HH; Rieß C; Deuschl C; Schmidt B; Jabbarli R; Wrede KH; Zhu Y; Frank B; Sure U; Dammann P
Eur J Neurol; 2022 May; 29(5):1427-1434. PubMed ID: 35060255
[TBL] [Abstract][Full Text] [Related]
29. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
Polster SP; Cao Y; Carroll T; Flemming K; Girard R; Hanley D; Hobson N; Kim H; Koenig J; Koskimäki J; Lane K; Majersik JJ; McBee N; Morrison L; Shenkar R; Stadnik A; Thompson RE; Zabramski J; Zeineddine HA; Awad IA
Neurosurgery; 2019 Apr; 84(4):954-964. PubMed ID: 29660039
[TBL] [Abstract][Full Text] [Related]
30. MRI-based quantitative susceptibility mapping (QSM) and R2* mapping of liver iron overload: Comparison with SQUID-based biomagnetic liver susceptometry.
Sharma SD; Fischer R; Schoennagel BP; Nielsen P; Kooijman H; Yamamura J; Adam G; Bannas P; Hernando D; Reeder SB
Magn Reson Med; 2017 Jul; 78(1):264-270. PubMed ID: 27509836
[TBL] [Abstract][Full Text] [Related]
31. Deep gray matter iron measurement in patients with liver cirrhosis using quantitative susceptibility mapping: Relationship with pallidal T
Lee S; Nam Y; Jang J; Na GH; Kim DG; Shin NY; Choi HS; Jung SL; Ahn KJ; Kim BS
J Magn Reson Imaging; 2018 May; 47(5):1342-1349. PubMed ID: 28815906
[TBL] [Abstract][Full Text] [Related]
32. Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.
Sone JY; Hobson N; Srinath A; Romanos SG; Li Y; Carrión-Penagos J; Shkoukani A; Stadnik A; Piedad K; Lightle R; Moore T; DeBiasse D; Bi D; Shenkar R; Carroll T; Ji Y; Girard R; Awad IA
J Magn Reson Imaging; 2022 May; 55(5):1440-1449. PubMed ID: 34558140
[TBL] [Abstract][Full Text] [Related]
33. Neuroimaging of Cavernous Malformations.
Mokin M; Agazzi S; Dawson L; Primiani CT
Curr Pain Headache Rep; 2017 Oct; 21(12):47. PubMed ID: 29030748
[TBL] [Abstract][Full Text] [Related]
34. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome.
Flemming KD; Kim H; Hage S; Mandrekar J; Kinkade S; Girard R; Torbey M; Huang J; Huston J; Shu Y; Lanzino G; Selwyn R; Hart B; Mabray M; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Lane K; McBee N; Treine K; Ostapkovich N; Wang Y; Thompson R; Koenig JI; Carroll T; Hanley D; Awad I
Stroke; 2024 Jan; 55(1):22-30. PubMed ID: 38134268
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Susceptibility Mapping for Following Intracranial Hemorrhage.
Sun H; Klahr AC; Kate M; Gioia LC; Emery DJ; Butcher KS; Wilman AH
Radiology; 2018 Sep; 288(3):830-839. PubMed ID: 29916778
[TBL] [Abstract][Full Text] [Related]
36. On the influence of zero-padding on the nonlinear operations in Quantitative Susceptibility Mapping.
Eskreis-Winkler S; Zhou D; Liu T; Gupta A; Gauthier SA; Wang Y; Spincemaille P
Magn Reson Imaging; 2017 Jan; 35():154-159. PubMed ID: 27587225
[TBL] [Abstract][Full Text] [Related]
37. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.
Wang Y; Spincemaille P; Liu Z; Dimov A; Deh K; Li J; Zhang Y; Yao Y; Gillen KM; Wilman AH; Gupta A; Tsiouris AJ; Kovanlikaya I; Chiang GC; Weinsaft JW; Tanenbaum L; Chen W; Zhu W; Chang S; Lou M; Kopell BH; Kaplitt MG; Devos D; Hirai T; Huang X; Korogi Y; Shtilbans A; Jahng GH; Pelletier D; Gauthier SA; Pitt D; Bush AI; Brittenham GM; Prince MR
J Magn Reson Imaging; 2017 Oct; 46(4):951-971. PubMed ID: 28295954
[TBL] [Abstract][Full Text] [Related]
38. Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging.
Flemming KD; Graff-Radford J; Aakre J; Kantarci K; Lanzino G; Brown RD; Mielke MM; Roberts RO; Kremers W; Knopman DS; Petersen RC; Jack CR
JAMA Neurol; 2017 Jul; 74(7):801-805. PubMed ID: 28492932
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Susceptibility Mapping of Intracerebral Hemorrhages at Various Stages.
Chang S; Zhang J; Liu T; Tsiouris AJ; Shou J; Nguyen T; Leifer D; Wang Y; Kovanlikaya I
J Magn Reson Imaging; 2016 Aug; 44(2):420-5. PubMed ID: 26718014
[TBL] [Abstract][Full Text] [Related]
40. Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.
Lanfranconi S; Scola E; Bertani GA; Zarino B; Pallini R; d'Alessandris G; Mazzon E; Marino S; Carriero MR; Scelzo E; Faragò G; Castori M; Fusco C; Petracca A; d'Agruma L; Tassi L; d'Orio P; Lampugnani MG; Nicolis EB; Vasamì A; Novelli D; Torri V; Meessen JMTA; Al-Shahi Salman R; Dejana E; Latini R;
Trials; 2020 May; 21(1):401. PubMed ID: 32398113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
